Patent details
EP1467762
Title:
USE OF A H1 ANTAGONIST AND RIMEXOLONE AS A SAFE STEROID TO TREAT RHINITIS
Basic Information
- Publication number:
- EP1467762
- PCT Application Number:
- PCT/US/2002/036915
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP028046944
- PCT Publication Number:
- WO/2003/049770
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- USE OF A H1 ANTAGONIST AND RIMEXOLONE AS A SAFE STEROID TO TREAT RHINITIS
- French Title of Invention:
- UTILISATION D'UN ANTAGONISTE H1 ET DU RIMEXOLONE COMME STEROIDE INOFFENSIF POUR TRAITER LA RHINITE
- German Title of Invention:
- VERWENDUNG EINES H1-ANTAGONISTEN UND VON RIMEXOLON ALS SICHERES STEROID ZUR BEHANDLUNG VON RHINITIS
- SPC Number:
-
Dates
- Filing date:
- 18/11/2002
- Grant date:
- 08/02/2006
- EP Publication Date:
- 08/02/2006
- PCT Publication Date:
- 19/06/2003
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 20/10/2004
- EP B1 Publication Date:
- 08/02/2006
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 18/11/2018
- Expiration date:
- 18/11/2022
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 18/11/2002
-
-
- Name:
- Alcon Inc.
- Address:
- Bösch 69, 6331 Hünenberg, Switzerland (CH)
Inventor
1
- Name:
- MILLER Steven T.
- Address:
- United States (US)
2
- Name:
- GAMACHE Daniel, A.
- Address:
- United States (US)
3
- Name:
- YANNI John, M.
- Address:
- United States (US)
Priority
- Priority Number:
- 337371 P
- Priority Date:
- 05/12/2001
- Priority Country:
- United States (US)
Classification
- Main IPC Class:
-
A61K 45/06;
Annual Fees
- Annual Fee Due Date:
-
- Annual Fee Number:
-
- Expected Payer:
-
- Last Annual Fee Payment Date:
- 08/11/2017
- Last Annual Fee Paid Number:
- 16
- Last Annual Fee Paid Amount:
- 230 Euro
- Payer:
- MARKS & CLERK LLP